Aging in Individuals with the FMR1 Mutation

American Journal on Mental Retardation

Volumn 109, Issue 2, 2004, Pages

  Jacquemont, S ^a   Farzin, F ^a   Hall, D ^b   Leehey, M ^b   Tassone, F ^c   Gane, L ^a   Zhang, L ^c   Grigsby, J ^d   Jardini, T ^a   Lewin, F ^e   Berry Kravis, E ^e   Hagerman, P J ^c   Hagerman, R J ^a,f  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF COLORADO   (United States)

^e RUSH UNIVERSITY MEDICAL CENTER   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; AMANTADINE; AMFEBUTAMONE; AMITRIPTYLINE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIPARKINSON AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CITALOPRAM; CLONAZEPAM; DONEPEZIL; FLUOXETINE; FRAGILE X MENTAL RETARDATION PROTEIN; GABAPENTIN; LEVODOPA; PAROXETINE; PRAMIPEXOLE; PRIMIDONE; PROPRANOLOL; SERTRALINE; TRIHEXYPHENIDYL; VENLAFAXINE;

ADULT; AGED; AGING; ATAXIA; AUTONOMIC DYSFUNCTION; CLINICAL FEATURE; COGNITION; DEMOGRAPHY; FACIES; FEMALE; FRAGILE X SYNDROME; GENE MUTATION; GENETIC COUNSELING; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; MUSCLE RIGIDITY; NEUROIMAGING; NEUROPATHY; PARKINSONISM; REVIEW; TREMOR;

AGED; AGING; BRAIN; COGNITION DISORDERS; FRAGILE X MENTAL RETARDATION PROTEIN; FRAGILE X SYNDROME; GENETIC COUNSELING; HEALTH STATUS; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NERVE TISSUE PROTEINS; POINT MUTATION; RNA-BINDING PROTEINS;

EID: 12144289389     PISSN: 08958017     EISSN: None     Source Type: Journal    
DOI: 10.1352/0895-8017(2004)109<154:AIIWTF>2.0.CO;2     Document Type: Review

References (42)

1. Aziz, M. E., Stathopulu, M., Callias, C., Taylor, J., Turk, B., Oostra, B., Willemsen, R., & Patton, M. (2003). Clinical features of boys with fragile X premutations & intermediate alleles. American Journal of Medical Genetics, 121B(1), 119-127.
2. Berry-Kravis, E., Lewin, F., Wuu, J., Leehey, M., Hagerman, R., Hagerman, P., & Goetz, C. G. (2003). Tremor and ataxia in fragile X premutation carriers: Blinded videotape study. Annals of Neurology, 53(5), 616-623.
3. Botez, M. I., Botez-Marquard, T., Elie, R., Pedraza, O. L., Goyette, K., & Lalonde, R. (1996). Amantadine hydrochloride treatment in heredodegenerative ataxias: A double blind study. Journal of Neurology, Neurosurgery, and Psychiatry, 61(3), 259-264.
4. Brunberg, J. A., Jacquemont, S., Hagerman, R. J., Berry-Kravis, E., Grigsby, J., Leehey, M., Tassone, F., Brown, W. T., Greco, C., & Hagerman, P. J. (2002). Fragile X premutation carriers: Characteristic MR imaging findings in adult males with progressive cerebellar and cognitive dysfunction. American Journal of Neuroradiology, 23, 1757-1766.
5. Chen, M., Ova, V. O., Li, M., Ferrante, R. J., Fink, K. B., Zhu, S., Bian, J., Guo, L., Farrell, L. A., Hersch, S. M., Hobbs, W., Vonsattel, J. P., Cha, J. H., & Friedlander, R. M. (2000). Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nature Medicine, 6(7), 797-801.
6. Dombrowski, C., Levesque, M. L., Morel, M. L., Rouillard, P., Morgan, K., & Rousseau, F. (2002). Premutation and intermediate-size FMR1 alleles in 10,572 males from the general population: Loss of an AGG interruption is a late event in the generation of fragile X syndrome alleles. Human Molecular Genetics, 11(4), 371-378.
7. Fininster, J. (2002). Myotonic dystrophy type 2. European Journal of Neurology, 9, 441-447.
8. Friedlander, R. M. (2003). Apoptosis and caspases in neurodegenerative diseases. New England Journal of Medicine, 348, 1365-1375.
9. Goodlin-Jones, B. L., Spence, S., Albrect, L., Bacalman, S., Tassone, F., Gane, L., Harris, S. W., Hagerman, P. J., & Hagerman, R. (2002, July 17-21). The fragile X premutation and autism. Presented at the 8th International Fragile X Conference, Chicago.
10. Greco, C., Hagerman, R. J., Tassone, F., Chudley, A., Del Bigio, M. R., Jacquemont, S., Leehey, M., & Hagerman, P. J. (2002). Neuronal intranuclear inclusions in a new cerebellar tremor/ataxia syndrome among fragile X carriers. Brain, 125, 1760-1771.
11. Grigsby, J., Hills, J., Wilson, R., Leehey, M., Hagerman, R. J., Tassone, F., & Hagerman, P. J. (2002). Dysexecutive syndrome in older men with action tremor and the fragile X premutation. Journal of the International Neuropsychological Society, 8(2), 282.
12. Grigsby, J., Leehey, M. A., Hagerman, R. J., Epstein, J. H., Wilson, R., Jacquemont, S., Greco, C. M., Brunberg, J. A., Tassone, F., & Hagerman, P. J. (2002). Dementia and a tremor-ataxia disorder among older male carriers of the fragile X premutation. Journal of the American Geriatrics Society, 50(Suppl), S48.
13. Hagerman, P., Iwahashi, C., Babineau, B., Yasui, D., Greco, C., Duncan, N., Graw, S., Kim, F., & Hagerman, R. (2003). Fragile X-associated tremor/ataxia syndrome (FXTAS): A common heritable neuronal inclusion disorder. Paper presented at the 55th annual meeting of the American Academy of Neurology, 60(Suppl 1), A469.
14. Hagerman, R. J., Leehey, M., Heinrichs, W., Tassone, F., Wilson, R., Hills, J., Grigsby, J., Gage, B., & Hagerman, P. J. (2001). Intention tremor, Parkinsonism, and generalized brain atrophy in male carriers of fragile X. Neurology, 57, 127-130,
15. Hagerman, R. J., Staley, L. W., O'Connor, R., Lugenbeel, K., Nelson, D., McLean, S. D., & Taylor, A. (1996). Learning-disabled males with a fragile X CGG expansion in the upper premutation size range. Pediatrics, 97(1), 122-126.
16. Hagerman, R. J., Zhang, L., Brunberg, J., Hessl, D., Jacquemont, S., Tassone, F., Harris, S., Jardini, T., & Hagerman, P. J. (2003). Two female cases of the fragile X premutation tremor/ataxia syndrome: Cognitive, molecular, and radiological studies. Paper presented at the 55th annual meeting of the American Academy of Neurology.
17. Hessl, D., Cohen, S., DeCarli, C., Tong-Turnbeaugh, R., Jacquemont, S., Gane, L., Jardini, T., Wegelin, J., Tassone, F., & Hagerman, P. J. (2003). Structural neuroimagine and molecular correlates of psychopathology in adult males with the FMR1 premutation. American Journal of Human Genetics, 53rd Annual Meeting, Los Angeles, CA, 73(Suppl)(5)A562, 266.
18. Jacquemont, S., Hagerman, R. J., Leehey, M., Greco, C., Brunberg, J., Tassone, F., Gane, L. W., Jardini, T., Harris, S. W., Zhang, L., Grigsby, J., Des Portes, V., Berry-Kravis, E., Brown, W. T., & Hagerman, P. J. (2002). Characterization of a progressive neurological condition in older adult male carriers of the fragile X premutation. American Journal of Human Genetics (Suppl 71, A), 107(4), 185.
19. Jacquemont, S., Hagerman, R. J., Leehey, M., Grigsby, J., Zhang, L., Brunberg, J. A., Greco, C., des Portes, V., Jardini, T., Levine, R., Berry-Kravis, E., Brown, W. T., Schaeffer, S., Kissel, J., Tassone, F., & Hagerman, P. J. (2003). Fragile X premutation tremor/ataxia syndrome: Molecular, clinical, and neuroimaging correlates. American Journal of Human Genetics, 72, 869-878.
20. Jacquemont, S., Hagerman, R. J., Leehey, M. A., Hall, D. A., Levine, R. A., Brunberg, J. A., Zhang, L., Jardini, T., Gane, L. W., Harris, S. W., Herman, K., Grigsby, J., Greco, C., Berry-Kravis, E., Tassone, F., & Hagerman, P. J. (2003). Penetrance of the fragile X-associated tremor/ataxia syndrome (FXTAS) in a premutation carrier population: Initial results from a California family-based study. American Journal of Human Genetics, 53rd annual meeting, Los Angeles, 73(Suppl)(5)A10, 163.
21. Jankovic, J., & Schwartz, K. (1991). Botulinum toxin treatment of tremors. Neurology, 41, 1185-1188.
22. Jankovic, J., & Tolosa, E. (2002). Parkinson's disease and movement disorders. Philadelphia: Lippincott, Williams, & Wilkins.
23. Kenneson, A., Zhang, F., Hagedorn, C. J., & Warren. S. T. (2001). Reduced FMRP and increased FMR1 transcription is proportionally associated with CGG repeat number in intermediate-length and premutation carriers. Human Molecular Genetics, 10, 1449-1454.
24. Kriz, J., Nguyn, M. D., & Julien, J. (2002). Minocycline slows disease progression in a mouse model of amyotropic lateral sclerosis. Neurobiology of Disease, 10, 268-278.
25. Leehey, M., Hagerman, R. J., Landau, W. M., Grigsby, J., Tassone, F., & Hagerman, P. J. (2002). Tremor/ataxia syndrome in fragile X carrier males. Movement Disorders, 17(4), 744-745.
26. Leehey, M., Munhoz, R., Lang, A. E., Brunberg, J., Grigsby, J., Greco, C., Jacquemont, S., Tassone, F., Lozano, A., Hagerman, P., & Hagerman, R. (2003a). The fragile X premutation presenting as essential tremor. Archives of Neurology, 60(1), 117-121.
27. Leehey, M. A., Munhoz, R. P., Lang, A. E., Brunberg, J. A., Grigsby, J., Greco, C., Jacquemont, S., Tassone, F., Lozano, A. M., Hagerman, P. J., & Hagerman, R. J. (2003b). The fragile x premutation presenting as essential tremor. Archives of Neurology, 60, 117-121.
28. Mankodi, A., Logigian, E., Callahan, L., McClain, C., White, R., Henderson, D., Krym, M., & Thornton, C. (2000). Myotonic dystrophy in transgenic mice expressing an expanded CUG repeat. Science, 289(5485), 1769-1773.
29. Mankodi, A., & Thornton, C. A. (2002). Myotonic syndromes. Current Opinion in Neurology, 15, 545-552.
30. McIntosh, N., Gane, L. W., McConkie-Rosell, A., & Bennett, R. L. (2000). Genetic counseling for fragile x syndrome: Recommendations of the National Society of Genetic Counselors. Journal of Genetic Counseling, 9, 303-325.
31. Perlman, S. (2000). Cerebellar ataxia. Current Treatment Options in Neurology, 2(3), 215-224.
32. Primerano, B., Tassone, F., Hagerman, R. J., Hagerman, P., Amaldi, F., & Bagni, C. (2002). Reduced FMR1 mRNA translation efficiency in fragile x patients with premutations. RNA, 8, 1482-1488.
33. Rousseau, F., Morel, M.-L., Rouillard, P., Khandjian, E. W., & Morgan, K. (1996). Surprisingly low prevalence of FMR1 premutation among males from the general population. American Journal of Human Genetics, 59(Suppl), A188, 1069.
34. Shults, C. W., Oakes, D., Kieburtz, K., Beal, F., Haas, R., Plumb, S., Juncos, J. L., Nutt, J., Shoulson, I., Carter, J., Kompoliti, K., Perlmutter, J. S., Reich, S., Stern, M., Watts, R. L., Kurlan, R., Molho, E., Harrison, M., Lew, M., & a. t. P. S. Group (2002). Effects of coenzyme Q10 in early Parkinson disease. Archives of Neurology, 59, 1541-1550.
35. Tassone, F., Hagerman, R. J., Taylor, A. K., Gane, L. W., Godfrey, T. E., & Hagerman, P. J. (2000). Elevated levels of FMR1 mRNA in carrier males: A new mechanism of involvement in fragile X syndrome. American Journal of Human Genetics, 66, 6-15.
36. Tassone, F., Hagerman, R. J., Taylor, A. K., & Hagerman, P. J. (2000, July 19-23). Transcriptional activity in fragile X males with full mutation alleles. Paper presented at the 7th International Fragile X Conference, Los Angeles.
37. Tassone, F., Hagerman, R. J., Taylor, A. K., & Hagerman, P. J. (2001). Fragile X males with methylated, full mutation alleles have significant levels of FMR1 messenger RNA. Journal of Medical Genetics, 38, 0-3.
38. Tassone, F., Orrico, A., Galli, L., Jacquemont, S., Hagerman, R., & Hagerman, P. (2002). Spastic parapresis and ataxia in two sisters with the fragile x premutation. National Fragile X Foundation's 8th International Fragile X Conference, Chicago.
39. Wasielewski, P. G., Burns, J. M., & Koller, W. C. (1998). Pharmacologic treatment of tremor. Movement Disorders, 13(3), 90-100.
40. Willemsen, R., Hoogeveen-Westerveld, M., Reis, S., Holstege, J., Severijnen, L. A., Nieuwenhuizen, I. M., Schrier, M., Van Unen, L., Tassone, F., Hoogeveen, A. T., Hagerman, P. J., Mientjes, E. J., & Oostra, B. A. (2003). The FMR1 CGG repeat mouse displays ubiquitin-positive intranuclear neuronal inclusions: Implications for the cerebellar tremor/ataxia syndrome. Human Molecular Genetics, 12(9), 949-959.
41. Willemsen, R., Mohkamsing, S., de Vries, B., Devys, D., van den Ouweland, A., Mandel, J. L., Galjaard, H., & Oostra, B. (1995). Rapid antibody test for fragile X syndrome. Lancet, 345(8958), 1147-1148.
42. Willemsen, R., & Oostra, B. A. (2000). FMRP detection assay for the diagnosis of the fragile X syndrome. American Journal of Medical Genetics, 97(3), 183-188.